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The willingness of patients to accept an additional mortality risk
in order to improve renal graft survival.
Background. This study was performed to assess renal trans-
plant patient preferences with respect to the acceptance of an
additional mortality risk induced by immunosuppressive ther-
apy in order to prevent graft loss in case of acute rejection.
Methods. The two decision analysis tools standard gam-
ble and time trade-off were used to interview 155 patients
with a functioning renal graft, and 11 on dialysis awaiting
transplantation.
Results. Defining the best possible outcome as being alive
with a functioning graft (utility value = 1), and the worst out-
come as dying (utility value = 0), median utility values of 0.68
(0.59 ± 0.32, mean ± SD) with standard gamble and of 0.65
(0.57 ± 0.32) with time trade-off were obtained for the inter-
mediate outcome (i.e., staying alive but returning to dialysis).
Thirteen percent of the patients attributed a utility value of 0
to this intermediate outcome (i.e., they would rather die than
return to dialysis), and 8% a utility value of 1 (i.e., they would
take absolutely no risk from additional antirejection therapy).
Individual utility values for returning to dialysis correlated with
time on dialysis before transplantation (R = 0.76, P < 0.005), but
no relationship was found between utility values and age, sex,
religion, previous methods of dialysis, time with a functioning
graft, number of transplantations, or time on the transplantation
waiting list.
Conclusion. The large interindividual variability of utility val-
ues precludes a prediction about the acceptance of a new thera-
peutic regimen by an individual patient. The assessment of the
utility enables, however, a more objective judgment of the gen-
eral acceptance of any possible risk/benefit ratio induced by a
new immunosuppressive regimen in our patient population.
Modern renal transplant medicine takes advantage
from a wide range of possible therapeutic regimens for
baseline immunosuppressive therapy as well as for the
treatment of acute rejections [1, 2]. Combinations of
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novel and traditional immunosuppressive drugs have cer-
tainly improved graft survival, but the advantages of
a more efficacious immunosuppression with respect to
transplant survival are troubled by an increased rate of
opportunistic infections and/or malignancies [3–15]. The
use of potent antibodies in renal transplant recipients has
been linked with an increased mortality [3], and higher
cyclosporine doses resulted in an increased rate of malig-
nancies when compared with lower cyclosporine doses
[16]. Furthermore, it is well established that infection
rates increase with more aggressive immunosuppressive
regimens [3, 14, 15, 17–20].
The decision to choose a therapeutic or prophylactic
regimen not only depends on the probabilities of the clin-
ical outcome, but also on the patient’s preference regard-
ing this outcome. The patient’s preferences for health
outcomes can be explicitly assessed and expressed in
quantitative terms known as utilities. So far, no data have
been available about the willingness of renal transplant
patients to accept an additional mortality risk in order
to improve the probability of renal graft survival during
acute rejection. Therefore, the present study was con-
ducted to assess the preference of renal transplant recip-
ients with respect to the prevention of graft loss versus
risk of death in case of acute rejection, and to relate indi-
vidual preference to patient characteristics and treatment
modalities.
Patient preferences were assessed by the two methods
standard gamble and time trade-off , respectively [21–23].
The standard gamble method is based on fundamental ax-
ioms of utility theory [24, 25], and is the original method
for measuring utilities. This method has been extensively
used in the field of decision analysis, and detailed descrip-
tions of the method are available [26]. The time trade-
off method has been derived from the standard gamble
method as a simple-to-administer alternative specifically
for use in health research [22].
METHODS
Renal transplant patients (N = 155) and hemodial-
ysis patients awaiting kidney transplantation (N = 11)
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Table 1. Baseline characteristics of patients participating at the
preference measurement interview (N = 166)
Count %
Age years
<20 4 (2%)
20 to 30 14 (8%)
30 to 50 73 (44%)
50 to 60 42 (25%)
80 to 70 30 (18%)
>70 3 (2%)
Gender
Male 96 (58%)
Female 70 (42%)
Marital status
Married 94 (57%)
Widowed 12 (7%)
Single 51 (31%)
Divorced 9 (5%)
Number of children
0 73 (43%)
1 23 (14%)
2 44 (27%)
3 17 (10%)
4 to 7 9 (5%)
Occupation
None, unskilled, or semiskilled 80 (48%)
Skilled 86 (52%)
Religion
Protestant Christian 114 (69%)
Catholic Christian 41 (25%)
Other 11 (7%)
Dialysis modality
Center hemodialysis 83 (50%)
Self-care hemodialysis 31 (19%)
Peritoneal dialysis 28 (17%)
Home hemodialysis 18 (11%)
Pretransplant duration of dialysis years
None 6 (4%)
<1 31 (19%)
1 to 2 44 (27%)
2 to 3 31 (19%)
3 to 5 27 (16%)
5 to 15 24 (14%)
>15 3 (2%)
Waiting time on transplantation list (N = 137)
None 1 (1%)
<3 month 35 (26%)
3 to 6 months 20 (15%)
6 months to 1 year 27 (20%)
1 to 3 years 36 (26%)
3 to 10 years 17 (12%)
>10 years 1 (1%)
were asked during outpatient follow-up visits to partic-
ipate in two short preference measurement interviews
(Table 1). The treating physician was present when pa-
tients were asked to participate at the interview, but not
during the interview itself. All interviews were done by
the same physician, who was unknown to the patients, and
had never been involved in taking medical care of these
subjects. Patients were informed that their preference
measurements were kept anonymously, and that these
measurements would not influence future decision mak-
ing by their treating physician. Both preference measure-
ment interviews were taken one after the other (standard
gamble followed by time trade-off ) during one session
that lasted about 30 minutes.
The following patient information was obtained and
considered for the analyses: sex, age, marital status, num-
ber of children, religion, occupation, previous method of
dialysis, duration of the present functioning graft, number
of transplantations, and time on the transplant waiting list
before transplantation (Table 1).
Assessment of patient preferences
The two preference measurement instruments, stan-
dard gamble and time trade-off , used for the present in-
vestigation have previously been described and discussed
[21, 27] (Fig. 1). In both interviews, patients were asked
to imagine the same virtual situation [i.e., an acute rejec-
tion episode of the renal graft refractory to conventional
immunosuppressive therapy (treatment A) that will re-
sult in a graft loss and a subsequent return to dialysis
therapy] [28–30]. Furthermore, patients were asked to
imagine a new hypothetical immunosuppressive regimen
(treatment B) that might succeed in reversal of the rejec-
tion episode and prevent a return to dialysis, but at the
risk of treatment-related death.
Using the standard gamble method [21], patients were
asked to choose between the following two alternatives
(Fig. 1): (1) Treatment A of the acute graft rejection
episode with no risk of dying, but graft loss and subse-
quent return to dialysis; and (2) Treatment B, resulting
in a gamble between a successful treatment of the rejec-
tion episode (remaining transplanted with a functioning
graft) with probability P, and a treatment-related death
with probability (1-P).
During the interview, probability P was varied until
the patient was indifferent with respect to the two alter-
natives. At that point, the utility value of the health state
with intermediate desirability (return to dialysis) corre-
sponds to the probability P of the best possible outcome.
The initial gamble for the outcome of treatment B
offered to patients was a 50% chance of staying trans-
planted, and a 50% chance to die from the therapy. These
probabilities were modified during the interview to 75%,
90%, 95%, 99%, 99.5%, 99.9% and 25%, 10%, 5%, 1%,
0.5%, 0.1%, respectively, dependent on the patients’ ini-
tial choice. If one probability was acceptable and the
other one was unacceptable to the patient, the inter-
view was continued at the mean value between these two
probabilities.
For ease of the studied patients to think in terms of
probabilities, the standard gamble was presented with the
aid of a probability wheel consisting of a disk with two
movable differently colored sections, which could be ad-
justed to represent the probabilities of the two gamble
alternatives P and (1-P) [27, 31, 32].
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Fig. 1. (A) Standard gamble. Lottery approach to decision making. The patient has to decide between an intermediate outcome (staying alive but
returning to dialysis) for certain, and a gamble between the best possible outcome (i.e., staying alive with a functioning graft with a probability P)
and the worst possible outcome (i.e., death with a probability 1-P). During the interview, probability P is varied until the patient is indifferent with
respect to the two alternatives. At that point the utility value of the health state with intermediate desirability (return to dialysis) corresponds to
the probability P of the best possible outcome. (B) Time trade-off. Decision between two certain outcomes. The patient has to decide to live either
his full life expectancy on chronic dialysis (t) or to remain transplanted for a shortened lifespan (x < t). The value of the shortened life expectancy
x is varied during the interview, until the patient is indifferent with respect to the two alternatives. At that point the utility value of the health state
with intermediate desirability (return to dialysis) is given by the proportion between the shortened life expectancy x and the full life expectancy of
the intermediate outcome t (U = x/t).
For the preference measurement with the time trade-
off method [21–23], patients were asked to imagine the
same virtual situation of an acute rejection episode refrac-
tory to standard immunosuppressive therapy. This time,
patients were not asked to choose between a certain in-
termediate outcome and a gamble between the best and
worst possible outcomes, but rather between two alterna-
tives of certainty [i.e., patients were asked to choose be-
tween: (1) Treatment A with consecutive graft loss and
return to dialysis for a given life expectancy of t years;
and (2) Treatment B, which saves the renal graft, but pro-
vides a shortened life expectancy of x years]. In other
words, patients were asked about how much of their life
expectancy they would be willing to trade-off in order to
remain transplanted (Fig. 1).
The value of the shortened life expectancy x was var-
ied during the interview, until the patient was indifferent
with respect to the two alternatives. At that point, the
utility value of the health state with intermediate desir-
ability (return to dialysis) was given by the proportion
between the shortened life expectancy x and the full life
expectancy of the intermediate outcome t (U = x/t).
Life expectancies offered to the patients were taken
from the 1995 USRDS Annual Data Report [33]. This
dataset provides estimates of life expectancies for United
States dialysis patients with and without diabetes mellitus
grouped by age, race, and sex. Our patients were offered
these life expectancies as pure assumptions without spec-
ification of their origin.
A reduction to one half of the full life expectancy with
treatment A was initially offered to save the transplant
with treatment B. This life expectancy was further halved
until the patient switched decision. Then, the mean value
between the actual and the most recent life expectancy
was offered to the patient until he became indifferent
with respect to the choice between treatment A and
treatment B.
Statistical analysis
Statistical analyses were performed with the help of
SYSTAT 10.0 (SPSS, Inc., Chicago, IL, USA) and S-Plus
6 (MathSoft, Inc., Seattle, WA, USA). Methods included
descriptive statistics, cross tables, and univariate, as well
as multivariate, complete and step-wise logistic regres-
sion analyses (i.e., linear regression models after logistic
transformation of the utilities). All mathematic formulas
are listed in the Appendix.
RESULTS
One hundred and sixty-six patients of the 173 patients
that were asked accepted to participate at the interview,
and 7 patients (6 women and one man, correspond-
ing to 4.1% of the target population) refused the inter-
view. The baseline characteristics of participating patients
at the preference-measurement interview are listed in
Table 1. The age of the interviewed patients ranged from
18 to 74 years. All patients were white with the excep-
tion of one black woman. One hundred fifty-five patients
were Catholic or Protestant Christians; the remaining
11 patients were Orthodox Christians, Jewish, Moslems,
Hindu, or had no religion.
Eighty-six patients (21 females) were working in skilled
professions, the others either did not work or they had
unskilled or semiskilled occupations (Table 1). Thirty-
three (5 females) of the skilled professionals were doing
traditional blue-collar work.
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Fig. 2. Distribution of the individually determined utility values from
166 patients. Empty bars represent the utility values obtained by stan-
dard gamble, black bars represent the values obtained by time trade-off .
Bar pairs are given for the following utility ranges: 0 to 0.1, 0.1 to 0.2, 0.2
to 0.3, . . . 0.9 to 1. A utility value toward 1 indicates that the patient does
not accept any risk from a more aggressive rejection therapy, whereas
a utility value toward 0 indicates that the patient accepts a substantial
reduction of life expectancy in order to avoid dialysis therapy.
Table 2. Summary of utilities obtained by standard gamble and time
trade-off methods
Standard gamble Time trade-off
Median 0.68 0.65
Range 0–1 0–1
Interquartile range 0.40–0.87 0.33–0.83
Mean ± SD 0.59 ± 0.32 0.57 ± 0.33
Of the 166 interviewed patients, 155 (93.4%) were re-
nal transplanted, and 11 were on chronic dialysis (6.6%)
awaiting first or second transplantation. Twenty patients
(12.1%) had been transplanted once before, and 4 pa-
tients (2.4%) had had two previous transplantations.
The pretransplant duration of dialysis ranged from 0 to
19 years. The time since the last transplantation ranged
from 0.04 to 23 years. Patients spent 0 to 16 years on
the transplantation waiting list before transplantation
(Table 1).
All 166 patients completed both standard gamble and
time trade-off assessments. Figure 2 shows the frequency
distribution of the individual utilities obtained by the
standard gamble method (empty bars) and the time trade-
off method (black bars). The corresponding mean and
median values are given in Table 2. Individual preference
values obtained by the standard gamble method were
correlated with those from the time trade-off method
(Spearman R = 0.747, P < 0.0001). Figure 4 relates the in-
traindividual differences in utilities assessed by standard
gamble and time trade-off to the average utility assessed
in each patient [34]. The spread of the data within the
distribution space is consistent with a random error dis-
tribution, but a minimum bias (+0.017) of the difference
between standard gamble and time trade-off is observed.
The influence of patient characteristics (Table 1) was
analyzed by univariate and multivariate linear regression
analysis after logistic transformation of the average util-
ities. Patient utilities were not influenced by age, marital
status, children (yes or no), the number of children, oc-
cupation, blue-collar or white-collar work, professional
work requiring a higher degree of education, religion,
pretransplant dialysis modality, the number of previous
transplantations, or the time since transplantation. Pa-
tient and treatment parameters that revealed a signifi-
cant influence on the average utility values were: female
gender (coefficient: −1.011, P < 0.02), the pretransplant
duration of dialysis (coefficient: 0.189, P < 0.002), and
waiting time on the transplant list (coefficient: 0.225, P <
0.03). Using a step-wise multivariate model including the
three parameters with a significant influence described
above revealed an independent influence of the pretrans-
plant duration of dialysis (P < 0.004) and female gender
(P < 0.04) on the average utility values. Waiting time on
the transplant list was related to pretransplant duration of
dialysis, and therefore failed to independently influence
the average utility values. Figure 5 shows the distribu-
tion of the average utilities by gender and pretransplant
duration of dialysis (categories selected for illustrative
purposes only).
During the standard gamble interview, 23 patients
(13.9%) assigned a utility value of 0 (i.e., they would
rather die than return to dialysis), and 9 patients (5.4%) a
value of 1 (i.e., they would take absolutely no risk) to the
intermediate outcome of staying alive but returning to
dialysis. During the time trade-off interview, 22 patients
(13.3%) assigned a value of 0, and 17 patients (10.2%)
a value of 1, respectively, to the intermediate outcome.
Twenty-one patients (13 females) assigned a utility value
of 0, and 8 patients (4 females) a utility value of 1 to the
intermediate outcome during both utility assessments.
The patients who assigned a utility value of 0 or 1 to
the intermediate outcome during any or both of the utility
assessment interviews were further analyzed.
Patients who assigned a utility value of 0 to the inter-
mediate outcome were older (55 ± 12 vs. 47 ± 13 years,
P < 0.002), and more of them were unoccupied or on an
unskilled or semiskilled occupation (17/80 vs. 7/96, P <
0.02). Significantly more women assigned a utility value
of 0 to the intermediate outcome (16/70 vs. 8/96, P < 0.01),
and 6 of the 12 widowed patients assigned a utility value
of 0 to the intermediate outcome during both interviews
(P < 0.001).
Five of the 6 widowed patients who assigned a utility
value of 0 during both interviews were women. Excluding
all widowed patients from analysis, neither influence of
gender on the assignment of a utility value of 0, nor on
the average utility values (see model above) was any
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Fig. 3. Decision tree describing a simplified
decision analysis for the selection of a drug
therapy during acute graft rejection (see Ap-
pendix).
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Fig. 4. Intraindividual differences in utilities assessed by standard gam-
ble (SG) and time trade-off (TTO) plotted against the average utility
assessed in each patient. The shaded area represents the theoretically
possible distribution space given by the constraint of utilities to val-
ues between 0 and 1. The horizontal lines represent the mean [+0.017]
(solid lines) ± 2 SD [+0.451 and –0.417] (broken lines).
longer detectable. No patient who dialyzed more than
5.2 years assigned a utility value of 0 to the intermedi-
ate outcome (i.e., return to dialysis) during any of the
interviews.
No influence of any patient or treatment parameters
on the assignment of a utility value of 1 was detected.
No differences in preferences between the 11 patients
on chronic dialysis and the transplanted patients were
detected.
Clinical use of the assessed patient preferences
The best possible medical therapy for a given popula-
tion can be selected if all outcome utilities are multiplied
by their probability of occurrence. The sum of all these
products gives the expected utility value of the therapy
(Fig. 3; Appendix). The treatment leading to the maxi-
mum expected utility value is considered to be the best
treatment. This approach is illustrated by the following
example: We assume a new immunosuppressive regimen
that increases graft survival after acute rejection from
75% to 85%, but decreases patient survival from 96% to
86%. This new regimen would not bring any advantage
for our patient population because 0.85 × 0.86 × 1 +
(1 – 0.85) × 0.86 × 0.67 = 0.82 is less than 0.75 × 0.96 × 1 +
(1 – 0.75) × 0.96 × 0.67 = 0.88. Calculations are based on a
utility value of 0.67, corresponding to the median patient
preference of our population. Unfortunately, few data are
available about success or treatment-related mortality of
new immunosuppressive drugs [3, 17–20]. Nevertheless,
new data emerge describing the advantages and disad-
vantages of new immunosuppressive regimens or dosings.
380 Girardi et al: Additional mortality risk in order to improve renal graft survival
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Ut
ilit
y
Male Female
Gender
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Ut
ilit
y
<3 yrs >10 yrs3–10 yrs
Dialysis treatment time
Fig. 5. Distribution of the average utilites by
gender (left) and pretransplant dialysis treat-
ment time (right). The lines in the boxes rep-
resent the median values, the width of the
boxes are equal to the interquartile range, and
the whiskers extend from the edges of the
boxes to the extreme values of the data.
DISCUSSION
We assessed the willingness of our renal transplant pa-
tients to accept an additional mortality risk in order to
increase renal graft survival during acute rejection. Both
methods used to obtain utility values, standard gamble
and time trade-off , revealed consistent results with me-
dian utility values of 0.68 and 0.65, respectively, in the
studied population (Table 2). These utility values for
the situation of staying alive, but returning to dialysis,
have to be interpreted in relation to the assumed utility
value of 1 for the best possible outcome (i.e., staying alive
with a functioning renal transplant)—in other words, our
patients value life on dialysis to be about two thirds of
the quality of living with a functioning graft.
No other data are available about the utility of dial-
ysis in relation to transplantation. One Canadian study
[35] assessed utility values of various renal replacement
therapies in relation to life with no renal replacement
therapy. Reported mean utility values obtained by time
trade-off were 0.43 ± 0.26 for in-center hemodialysis,
0.49 ± 0.23 for self-care or home hemodialysis, 0.56 ±
0.29 for peritoneal dialysis, and 0.84 ± 0.24 for renal
transplantation, respectively. A more recent study from
the Netherlands reported much higher utility values for
hemodialysis and peritoneal dialysis patients assessed by
standard gamble and time trade-off (0.82 to 0.89) [36].
Our findings are closer to the Canadian data, given the
fact that our utility values were assessed in relation to
life with a functioning graft, and not in relation to perfect
health.
Individual assignment of utility values was not sig-
nificantly influenced by patient age, sex, marital status,
number of children, or religion. Because 155 of the 166
patients from our population were Christian, the findings
cannot be extrapolated to predominantly non-Christian
populations. We did not find a significant relation-
ship between specific baseline characteristics (time since
transplantation, time on the transplantation waiting list,
pretransplant dialysis modality) and the utility values as-
signed by our patients, except for the pretransplant dura-
tion of dialysis. The significant relationship between the
pretransplant duration of dialysis and the utility value of
dialysis may be caused by a selection bias or because peo-
ple were getting used to longstanding dialysis therapy, and
therefore less willing to take any risks that might compro-
mise future survival.
We have demonstrated a significant relationship be-
tween the individual utility values estimated by standard
gamble and time trade-off , respectively, in our patient
population. Nevertheless, the relationship between time
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trade-off and standard gamble deviates slightly from iden-
tity (time trade-off = 0.1 + 0.8 × standard gamble), mean-
ing that patients are slightly more willing to trade off some
future survival time as long as the trade-off is predictable
and no risk is involved. This influence of ‘risk aversion’
on the assessment of patient preferences has previously
been described [37]. Another explanation might be that
the standard gamble method confronts the patient with a
risk to die, while the time trade-off method is presented as
a chance to survive. It is known that the term of survival
influences both patients and physicians toward a treat-
ment with a better long-term survival [38]. The similar
distribution of the utility values obtained by the two dif-
ferent measurement methods standard gamble and time
trade-off (Fig. 2) suggests, however, that these two meth-
ods measure by and large similar aspects of patients’
preferences.
Within various health states, and regardless of the as-
sessment method, utilities have been demonstrated to
vary within a broad range [27, 39]. This broad range is
given by the fact that the imagination of perfect health,
as well as the actual quality of life, is experienced very
subjectively. It is therefore not unexpected that healthy
patient populations show a broader variation of utility
values compared with very sick patients.
The high interindividual variability of utilities observed
in our patient population was not unexpected. We knew
from clinical experience before doing this study that some
of our transplanted patients would rather die than return
to dialysis, and we actually have seen people dying who
chose not to return to dialysis when their graft was failing.
Nevertheless, several methodologic problems might have
added to the observed variability of utilities. Individual
patients are generally inconsistent within themselves and
rather high test-retest variabilities [27, 39, 40] have been
reported. Some patients might have misunderstood the
questioning, and intra- and inter-interviewer variability
with respect to interviewing skills in communication with
the patient, instructing the patients on the techniques, and
actually taking the interviews, might have further added
to the observed high total variability of the assessed
utilities. All our interviews were given by the same in-
dividual, and were done structured after training of the
interviewer for these specific interviews. We could there-
fore avoid an inter-interviewer variability and minimize
the intra-interviewer variability [41–43]. However, be-
cause all interviews were given by the same person, and
because there is no gold standard to obtain “true” utility
values, we cannot exclude a bias introduced by the inter-
viewer or by the framing of the structured interview [37].
Nevertheless, there is little reason to believe that more in-
formal procedures in which the treatments are described
in general terms without quantitative statistical data are
less susceptible to the effects of different methods of
presentation [38].
Average population utility values can never be used
as a decision tool for an individual patient in a specific
situation [40]. Fortunately, there is usually no need for
such a tool during an acute graft rejection. In this sit-
uation, therapeutic options can be discussed with the
patient, carefully balancing risks and benefits of vari-
ous therapeutic options according to the specific situa-
tion, and according to individual preferences. Decision
tools based on average population utility values are, how-
ever, important when decisions are taken concerning ei-
ther a given patient with no possibility to learn about
his individual preference, or future therapeutic strate-
gies for a large group of patients. A decision concern-
ing the total population in clinical practice is the selec-
tion of the baseline immunosuppressive therapy after
transplantation. Except for patients with a special risk
profile, this baseline immunosuppressive therapy is usu-
ally the same for all patients in a transplantation center.
Large differences in the type and amount of baseline im-
munosuppression are noted between different transplan-
tation centers, ranging from standard therapies with pred-
nisone and cyclosporine alone to more powerful triple
or quadruple therapies, including new immunosuppres-
sive drugs and/or antibodies. These differences probably
reflect rather physicians’ than patients’ utilities because
assessment of the patients’ preferences has not been per-
formed in the past. We cannot exclude, however, that the
preference of patients and physicians coincide and differ
from center to center.
CONCLUSION
The presented data reveal that patients accept a re-
duction of life expectancy by about one third when they
have a choice to maintain a functioning allograft instead
of returning to dialysis treatment. This finding is proba-
bly in line with the same, not evidence-based opinion of
experienced clinicians. Apparently, transplanted patients
prefer a functioning graft to dialysis treatment; however,
they are not willing to accept unlimited hazards.
APPENDIX (see Figure 3)
I) General formulation of the Expected Utility (EU)
EU = p × u
where
EU = expected utility
p = probability of a clinical event
u = utility value
II) Expected utility of any treatment
EU = ((1 − p) × q × 1.00) + ((1 − p) × (1 − q) × x) + (p × 0.00)
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where
p = probability of treatment related mortality
q = probability of reversal of rejection
0.00 = utility value for death
1.00 = utility value for staying alive with a functioning graft
x = utility value for the intermediate outcome of staying alive
but returning to dialysis
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